Centre for Health Systems and Safety Research, Australian Institute of Health Innovation, Macquarie University, Sydney, New South Wales, Australia.
Department of Nephrology, Prince of Wales Hospital and Clinical School, University of New South Wales, Sydney, New South Wales, Australia.
Intern Med J. 2023 Sep;53(9):1625-1633. doi: 10.1111/imj.15938. Epub 2022 Oct 20.
Medications remain an important contributor to the development of acute kidney injury (AKI). This study aimed to examine associations between (i) administration of medications known to reduce glomerular filtration rate (GFR), that is, GFR modifiers and subsequent hospital-acquired AKI; and (ii) potentially medication-related AKI and patient adverse outcomes.
A retrospective cohort study utilising electronic health record data of patients admitted to a tertiary hospital in Australia in 2015. Timing of medication administration was compared with timing of AKI development. AKI cases were identified using an algorithm based on serum creatinine level changes. Multilevel regression models were applied with adjustment for relevant demographic and clinical factors.
Among 11 503 admissions, AKI was identified in 955 patients (8.3%) and 637 (66.7% of 955) were preceded by administration of a GFR modifier. Patients without prior AKI were 17% more likely to develop AKI after administration of these medications (adjusted odds ratio 1.17, 95% confidence interval (CI) 1.003-1.37). Older age and comorbidity with diabetes, acute myocardial infarction, peripheral vascular disease, liver cirrhosis and multiple myeloma were also significant predictors. Patients with potentially medication-related AKI were 11.69 times more likely to die in hospital (95% CI 7.84-17.43) and stayed 3.49 times longer in hospital (95% CI 3.26-3.73), compared with those without AKI.
Administration of medications contributing to the reduction of GFR is associated with an increased risk of hospital-acquired AKI and worse patient outcomes. Caution is required when prescribing these medications to patients at risk of developing AKI, and monitoring patients for deterioration is needed if administered.
药物仍然是急性肾损伤(AKI)发展的重要原因。本研究旨在探讨(i)已知降低肾小球滤过率(GFR)的药物(即 GFR 调节剂)的使用与随后发生的医院获得性 AKI 之间的关联;以及(ii)潜在与药物相关的 AKI 与患者不良结局之间的关联。
本研究使用澳大利亚一家三级医院 2015 年电子健康记录数据进行回顾性队列研究。比较药物使用时间与 AKI 发生时间。使用基于血清肌酐水平变化的算法确定 AKI 病例。应用多水平回归模型,调整相关人口统计学和临床因素。
在 11503 例住院患者中,955 例(8.3%)患者发生 AKI,其中 637 例(955 例的 66.7%)在 AKI 发生前使用了 GFR 调节剂。未发生 AKI 的患者在使用这些药物后发生 AKI 的可能性增加 17%(调整后的优势比 1.17,95%置信区间 1.003-1.37)。年龄较大以及合并糖尿病、急性心肌梗死、外周血管疾病、肝硬化和多发性骨髓瘤也是显著的预测因素。与无 AKI 的患者相比,有潜在与药物相关 AKI 的患者住院期间死亡的风险增加 11.69 倍(95%置信区间 7.84-17.43),住院时间延长 3.49 倍(95%置信区间 3.26-3.73)。
使用降低 GFR 的药物与医院获得性 AKI 风险增加和患者结局恶化相关。在有发生 AKI 风险的患者中使用这些药物时应谨慎,并在使用后对患者进行监测,以防止病情恶化。